Gamida Cell Ltd. (GMDA) NASDAQ
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
Gamida Cell Ltd.
Address
5 Nahum Heftsadie Street
Jerusalem, 91340
Israel
Phone
972 2 659 5666
Website
Sector
Healthcare
Industry
Biotechnology
Employees
143
First IPO Date
October 26, 2018
Key Executives
| Name | Title | Pay | Year Born |
| Abigail L. Jenkins | President, Chief Executive Officer & Director | 554,053 | 1976 |
| Joshua F. Patterson | General Counsel & Chief Compliance Officer | 479,000 | 1977 |
| Ronit Simantov | Chief Medical Officer & Chief Scientific Officer | 592,000 | 1965 |
| Michele Ilene Korfin | Chief Operating & Chief Commercial Officer | 606,000 | 1972 |
| Tracey Lodie | Scientific Advisor & Consultant | 0 | 1970 |
| Vladimir Melnikov | Senior Vice President of Global Operations & Manufacturing | 0 | N/A |
| Linda Stamler | Vice President of Marketing & Account Management | 0 | N/A |
| Penny Bushell | Chief Human Resource Officer | 0 | N/A |
| Naftali Brikashvili | Senior Vice President Finance & Operations | 0 | N/A |
| Mary Theresa Coelho | Chief Financial Officer, Principal Financial Officer & Principal Accounting Officer | 0 | 1963 |
Description
Gamida Cell Ltd. operates as a clinical-stage biopharmaceutical firm, dedicated to pioneering cell therapies aimed at eradicating blood cancers and other severe hematological conditions. The company's leading investigational product, omidubicel—a specialized cell therapy—has successfully concluded its Phase III clinical evaluation for individuals afflicted with high-risk hematologic malignancies. Furthermore, it is currently undergoing Phase I/II trials for patients suffering from severe aplastic anemia. Another significant therapeutic candidate, GDA-201, an immunotherapy harnessing natural killer cells, is progressing through Phase I/II studies to address relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. Beyond these, Gamida Cell is actively advancing a broader natural killer (NK) cell pipeline, which includes GDA-301, GDA-401, GDA-501, and GDA-601, with the ambition of treating both hematologic cancers and solid tumors. Founded in 1998, the company maintains its corporate headquarters in Jerusalem, Israel.
